Product Description
Genervon was developing gm-604, an intravenous IGF Binder GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system for Amyotrophic Lateral Disease. (Sourced from: https://www.genervon.com/clinical-trials)
Mechanisms of Action: IGF Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genervon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GALS | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2014-04-01 |
32% |